Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. - Wikidata - wikimedia - TriplyDB

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

http://www.wikidata.org/entity/Q50716088

about

Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.Recent therapeutic advances in chronic lymphocytic leukemia.PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.Discovery and application of immune biomarkers for hematological malignancies.Treatment of Richter's Syndrome.Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.Cardiotoxicity of immune checkpoint inhibitors.Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors Anti-PD-1 therapy for clinical treatment of lymphoma: a single-arm meta-analysis Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations

P2860

Q38646074-A4A1590F-878D-4EE9-8D6B-8EA100AE6FBC Q42352191-6C59496F-086F-4200-801F-4B3035767A13 Q46318389-2E3E7E4E-DB0A-4BD6-87AE-2C7E4C35FFAA Q47120629-D57B8120-6244-439A-A059-13F0A9D6CA5F Q47329066-6E1E2B40-0C10-4C90-B2A9-E886CBA59A9D Q47424027-DE8F3934-BE5D-4E78-B399-CB248CFD8DC9 Q47681393-D1A02E9A-FC84-4CE3-998E-4ED09DE174CC Q49843910-4D36C887-0EBA-47BA-942F-3C1DE9A2F12F Q50074012-0188B7EE-C645-444F-B117-1FD512DC69B8 Q50110556-D43C1FC8-400C-454D-8E15-E50207F134F1 Q51804722-E8A86CB1-7877-4DF2-89FC-FBDFF7889632 Q52721221-361A3255-B43A-464A-9CCA-12AC14817AB5 Q54979456-B0040787-410D-4651-A62C-A5648CD47F48 Q55438414-C6239F46-8B50-4F84-8792-EF3985EC0B96 Q56891212-3190DCEA-41AD-42DF-B75E-732785E70FB6 Q58691451-BCA448C2-40CA-4248-A62F-5A7514F7A9E5 Q58713932-87D556B3-AD91-40C4-BD02-BA99B2073196 Q59132267-520EB8F5-438F-485E-967E-7131CC413B58 Q59135661-9C9CAE03-737E-4839-B2B8-CE85186760D7

P2860

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

http://www.wikidata.org/entity/Q50716088

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

@en

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

@nl

type

label

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

@en

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

@nl

prefLabel

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

@en

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

@nl

P1433

Q50716088-8270539C-CA9C-4215-ADF1-753142F14A84

P1476

Q50716088-BA245F14-49E6-4EED-89A0-B1B5D5F5FB55

P2093

Q50716088-0511805B-520B-43FA-B700-D0AF37A14C8A

Q50716088-07EFA536-1BE5-4AC8-96EE-B9CA3DC554D2

Q50716088-0E889EA4-0596-4567-AB15-1AB7AF72E0A2

Q50716088-0FF328CF-B6C5-4EA0-A0B1-E11771E7177A

Q50716088-1595D81F-60ED-4EBE-84D7-B20A1AC86540

Q50716088-306C3D5C-4A7A-4786-86F9-9F57D29E67CF

Q50716088-3570BB91-3E78-4031-B251-4D36D7546028

Q50716088-3B820EFE-7A37-4C30-B8C6-6A00BAE45E8B

Q50716088-44B60398-BF36-4B2E-BEB8-529EAC913E99

Q50716088-4765A8EA-C3EC-4EF8-84DD-8D096ADCA93A

P2860

Q50716088-0B8B213C-AC36-46B9-9004-7075FA9EE6C2

Q50716088-0C2179A0-11BD-4A02-946F-28D735C148D7

Q50716088-0E355094-0991-4E7D-8C85-8DC6442A7201

Q50716088-0E608A21-1ED5-4497-94DA-824C176D5ACE

Q50716088-0F74BC9B-5905-4FCE-88E3-7F80E8E61508

Q50716088-10F56A6C-641B-467A-9FD2-6992EC2DA6A0

Q50716088-1290F321-60BE-4EE7-B49F-13EA0F840F4F

Q50716088-229781C7-4975-4F17-94D5-4844FD712580

Q50716088-231DEDE6-74AD-4C3F-A995-9DBD99B4401E

Q50716088-26A20017-5B61-4681-8801-BE7887A2A398

P304

Q50716088-16773D1C-E646-4B7D-AFBF-5B59ABDFADC3

P31

Q50716088-3EC17BAE-115B-4B0D-8DB1-75DFCD478839

P356

Q50716088-D1878828-DFB5-4CDF-A251-712008A651E2

P407

Q50716088-25595FFB-849D-4893-B629-99720D568A29

P433

Q50716088-286CCEB6-A0F0-4A68-8D11-345DE40E562A

P478

Q50716088-03C30551-6228-4A7D-BD14-E1875F539ED4

P50

Q50716088-76ABC811-CF8B-4D09-8BC1-D7B4D68FEDD6

P577

Q50716088-92F7A9D6-A279-438B-AFC1-973CA4B1B42E

P698

Q50716088-8DCDB69C-3E19-46A5-BF35-91D92FF22BCF

P932

Q50716088-CF619F74-7B92-4331-94A5-C89C6DC718A4

P356

BLOOD-2017-02-765685

P1433

P1476

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

@en

P2093

Andrew L Feldman

http://www.w3.org/2001/XMLSchema#string

Asher A Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

Betsy R LaPlant

http://www.w3.org/2001/XMLSchema#string

Casey N Aitken

http://www.w3.org/2001/XMLSchema#string

Charla R Secreto

http://www.w3.org/2001/XMLSchema#string

Daniel L Van Dyke

http://www.w3.org/2001/XMLSchema#string

David S Viswanatha

http://www.w3.org/2001/XMLSchema#string

Deborah A Bowen

http://www.w3.org/2001/XMLSchema#string

Erik Asmus

http://www.w3.org/2001/XMLSchema#string

Esteban Braggio

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Pembrolizumab for the treatment of non-small-cell lung cancer

P304

3419-3427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2017-02-765685

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Jennifer Le-Rademacher

P577

2017-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28424162

http://www.w3.org/2001/XMLSchema#string

P932

5492091

http://www.w3.org/2001/XMLSchema#string